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Background: This is the first prospective, randomized, double-
blind, placebo-controlled study showing statistical improvement
of an H1-antihistamine in children with seasonal allergic rhini-
tis in all symptoms throughout the entire treatment period. 
Objective: This randomized, placebo-controlled, parallel-
group, double-blind study was performed to assess the efficacy
and safety of fexofenadine in children with seasonal allergic
rhinitis.
Methods: This study was conducted at 148 centers in 15
countries. Nine hundred thirty-five children (aged 6-11 years)
were randomized and treated with either fexofenadine HCl 30
mg (n = 464) or placebo (n = 471) tablets twice a day for 14
days. Individual symptoms (sneezing; rhinorrhea; itchy nose,
mouth, throat, and/or ears; itchy, watery, and/or red eyes; and
nasal congestion) were assessed at baseline and then daily at
7:00 AM and 7:00 PM (±1 hour) during the double-blind treat-
ment period. Each total symptom score was the sum of all
symptoms, excluding nasal congestion. The primary efficacy
variable was the change from baseline in the average of the
daily 12-hour evening reflective total symptom scores through-
out the double-blind treatment. Safety was evaluated from
adverse-event reporting, vital signs, physical examinations,
and clinical laboratory data at screening and study end point.
Results: Fexofenadine was significantly superior to placebo in
the primary efficacy analysis (P ≤ .0001). Individual symptom
scores showed statistically significant superiority compared
with placebo (P < .05), including nasal congestion in the
evening reflective assessment (P < .05). There was no signifi-
cant difference in adverse events between fexofenadine and
placebo, either overall or by causality.
Conclusion: The efficacy and safety of the H1-antihistamine
fexofenadine has been confirmed in this multicenter, multina-
tional study of children aged 6 to 11 years with seasonal aller-
gic rhinitis. (J Allergy Clin Immunol 2003;111:763-9.)
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Allergic rhinitis is the most common chronic condi-
tion in children.1 Estimates of its prevalence in children,
which varies from country to country, have been report-
ed to be as high as 40%,2 and it has been reported that the
incidence of allergic rhinitis in children is rising.3
The symptoms of seasonal allergic rhinitis (SAR),
including sneezing, rhinorrhea, nasal congestion, and the
associated symptoms of itchy nose, palate, throat, and/or
ears and itchy watery, and/or red eyes, can have a consid-
erable impact on patients’ quality of life and activities of
daily living. Data indicate that almost a million school
days are missed per year as a direct result of allergic rhini-
tis in the United States.4 In addition, children with untreat-
ed allergy symptoms exhibit lower learning ability at
school compared with nonallergic children.5 Furthermore,
if left untreated, allergic rhinitis can potentially exacerbate
and contribute to asthma6 as well as other comorbidities
such as conjunctivitis, otitis, dental malocclusions, sinusi-
tis, respiratory infections, and learning problems.7-12
Antihistamines have been a valuable allergic rhinitis
treatment for decades, and data from studies in adult pop-
ulations have been widely reported. Although some stud-
ies have assessed symptom relief of SAR in children
using antihistamines,13-18 including a postmarketing sur-
veillance program,19 only one study13 has used the same
end points as assessed in adult clinical studies. Fexofen-
adine (Allegra, Aventis) is a nonsedating, nonimpairing,
selective H1-receptor antagonist approved for the treat-
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ment of SAR. Large, randomized trials have been per-
formed in adults to show the efficacy and safety of this
agent in SAR.20-23 Previous studies have shown that
doses of fexofenadine HCl up to 60 mg 2 times per day
(bid) are safe and well tolerated in children aged 6
through 11 years.24,25 The present study was conducted
to confirm the efficacy and safety of twice-daily dosing
of fexofenadine HCl (30 mg bid) compared with placebo
in the treatment of SAR in children.
METHODS
Patients
Children aged 6 through 11 years with spring or fall SAR (aller-
gic to pollens of the appropriate season) and an approximate 1-year
history of SAR were enrolled. A positive skin prick test result
(wheal diameter ≥3 mm compared with diluent within 15 minutes
of the skin prick) to at least 1 allergen indigenous to the study site
area or, when relevant, to a child’s site of residence, which must
have been positive in serum allergen-specific IgE testing, was
required. In addition, the appropriate sensitizing allergen was
required to be present at visit 1 and likely to be present for 3 weeks
from visit 1. Children also needed to satisfactorily demonstrate that
they could swallow the study medication. 
At visit 1 (baseline), each child (with the help of his or her care-
giver) provided a 12-hour reflective assessment of the severity of the
allergy symptoms. Symptoms included the following: sneezing; rhi-
norrhea; itchy nose, palate, throat, and/or ears; itchy, watery, and/or
red eyes; and nasal congestion. Each symptom was evaluated on a 5-
point scale: 0 = absent; 1 = mild; 2 = moderate; 3 = severe; and 4 =
very severe. A total symptom score (TSS) was calculated by adding
the individual symptom scores, excluding nasal congestion (maxi-
mum possible TSS = 16). A reflective TSS of ≥6 at the initial visit,
with 2 or more symptoms with a minimum score of 2 (moderate),
was necessary for entry into the trial. Blood samples were taken at
visit 1 for allergen-specific assays of IgE of the individual allergen(s)
from the skin prick test or for each individual allergen in a mixture.
As far as possible, individual allergens were tested. Serum-specific
IgEs were determined by the Fluoro Enzyme Immuno Assay tech-
nique (UNICAP, Pharmacia), and a positive serum allergen-specific
IgE was defined as IgE class ≥2 (≥0.7 kUA/L).
Exclusion criteria included (but were not limited to) the follow-
ing: an upper respiratory tract infection within 30 days of the study;
purulent conjunctivitis or rhinitis of any type other than SAR;
obstructive deviated nasal septum or obstructive nasal polyposis;
active perennial allergic rhinitis; cystic fibrosis; immunotherapy to
treat SAR; and clinically significant cardiovascular, hepatic, neuro-
logic, psychiatric, endocrine, or other major systemic disease.
Drugs that were excluded included oral, nasal, and inhaled corti-
costeroids for 30, 14, and 30 days, respectively, before visit 1, and
inhaled or oral cromolyn sodium for 14 days before the visit. Chil-
dren were also excluded from the trial if nasal congestion was con-
sidered very severe. Between visits 1 and 2, the following drugs
were excluded: (a) the H1-receptor antagonists astemizole, lorata-
dine, fexofenadine, and cetirizine; (b) leukotriene modifiers, such as
montelukast and zafirlukast.
The study protocol was approved by institutional review boards,
and an informed-consent form was obtained from the parent/
guardian and the child before inclusion.
Study design
This double-blind, randomized, parallel-group, placebo-con-
trolled study was conducted at 148 centers in 15 countries, as fol-
lows: Argentina (16), Australia (9), Austria (1), Chile (3), Finland
(3), France (12), Germany (5), Israel (3), Italy (7), Poland (10), Por-
tugal (2), South Africa (18), Spain (6), Uruguay (2), and the United
States (51).
The study included 5 visits, as follows: screening (visit 1, day –8
to day –4), randomization (visit 2, day 1), during double-blind treat-
ment (visit 3, day 6 to day 10), end of double-blind treatment (visit
4, day 15 to day 17), and follow-up (visit 5, day 22 to day 24). Chil-
dren who met symptom criteria at visit 1 entered a 5- to 9-day, sin-
gle-blind, placebo lead-in phase. After completion of this phase,
each child was required to have an average TSS of ≥5 for the last 2
7:00 PM reflective TSSs (excluding nasal congestion) to qualify for
randomization to the double-blind phase of the study. Each child
was also required to have a concordant positive IgE skin prick test
result and positive serum IgE test result for randomization, in addi-
tion to the presence of the appropriate pollen at visit 1 and its like-
ly presence for 3 weeks. Compliance was assessed by tablet counts
at visit 2 (day 1) for the single-blind medication and at visit 3 (days
6-10) and visit 4 (days 15-17) for the double-blind treatment; any
child who had either missed >1 dose or taken an extra dose was
excluded from the study. The caregiver was instructed to administer
or supervise the administration of the study medication.
Children were randomized to receive either fexofenadine HCl 30
mg bid or matching placebo. Tablets were taken at 7:00 PM and 7:00
AM (±1 hour) for 2 weeks, with no dosing instructions regarding
food intake. SAR symptoms were assessed daily at 7:00 AM and
7:00 PM (±1 hour) for the previous 12-hour period (hereafter
referred to as AM-reflective and PM-reflective, respectively) by the
child and caregiver immediately before dosing. Diary cards were
collected at visits 2, 3, and 4 (though visit 3 was not mandatory).
Assessments: efficacy analysis
The primary efficacy variable was the mean change from base-
line in the average PM-reflective TSS throughout the double-blind
treatment period (also calculated as mean percentage change from
baseline). The secondary efficacy variables were the AM-reflective
TSS, the PM- and AM-reflective individual SAR symptom scores,
and the daily PM-reflective TSS. 
Assessments: safety analysis
Children recorded any adverse events (AEs) that occurred during
the study. The investigator also assessed the children for AEs and
instructed the children to report any events that occurred during the
study. Laboratory tests were performed at visits 1 and 4. Physical
examinations, including vital signs measurements, were performed
at visits 1, 2, and 4. (In those cases in which visit 3 was made, AEs
as well as vital signs were recorded.) Vital signs included systolic
and diastolic blood pressure, respiratory rate, and heart rate.
Statistical analysis
Analyses were undertaken on the modified intention-to-treat
(mITT) population. This was defined as all randomized children
who received at least 1 dose of double-blind treatment and had a
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PP: Per protocol
qid: Four times per day
SAR: Seasonal allergic rhinitis
TEAE: Treatment-emergent adverse event
TSS: Total symptom score
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baseline and at least 1 double-blind period PM-reflective assessment.
Demographic and baseline characteristics were compared between
treatment groups by Wilcoxon rank-sum tests for continuous vari-
ables and Fisher exact tests for categoric variables. Analysis of
covariance was used to compare the effects of fexofenadine HCl 30
mg bid with those of placebo. For the primary efficacy analysis, the
baseline score (randomization baseline TSS for AM and PM was
defined as the average of assessments during the placebo single-
blind period on day –2, day –1, and day 1 before double-blind treat-
ment) was included as a continuous covariate, and treatment and
pool center were included as fixed effects. A 2-sided 95% CI of the
treatment difference was derived by adjusted (least-squares) mean
from the analysis of covariance. Secondary efficacy variables were
analyzed by the same model. The number of children with at least
1 treatment-emergent AE (TEAE) was compared between the treat-
ment groups by Fisher exact test.
RESULTS
Demographics
Of 1961 children screened, 935 received study med-
ication (n = 464 fexofenadine; n = 471 placebo). The
most common reasons for nonrandomization (visit 1 and
visit 2) were positive IgE test results (n = 499), a low TSS
(n = 383), and the lack of a positive skin prick test result
(n = 219). Three children were excluded from the mITT
population because of the lack of postbaseline PM-reflec-
tive TSS data, leaving a total of 932 children in the mITT
population (n = 469 placebo; n = 463 fexofenadine). Of
these 932 children, 781 had no major protocol violations
and were classified as protocol-correct (per protocol [PP]
population). Nine hundred children completed the study.
Seven children withdrew from the study because of treat-
ment failure (fexofenadine, n = 3; placebo, n = 4). In all
instances the frequency of withdrawals was similar
across treatment groups. Treatment duration in the mITT
population was also comparable between groups, with a
median of 15 days and a mean of 15.3 days for each treat-
ment group. The mean number of doses of double-blind
treatment taken by the children in the mITT population
was 28.5 (fexofenadine, 28.6; placebo, 28.4).
There were no statistically significant differences in
baseline characteristics (including baseline PM-reflective
individual symptom scores and TSS), between treatment
groups apart from sex (P = .0417; Table I). Children in
the mITT population had a median age of 9 years (mean,
8.8 years; range, 5-12 years). The numbers of children
who had histories of allergy other than SAR were 271
(58.5% of 463) for the fexofenadine-treated group and
273 (58.2% of 469) for the placebo-treated group. The
numbers of children who had histories of asthma were
133 (28.7% of 463) for the fexofenadine-treated group
and 141 (30.1% of 469) for the placebo-treated group.
Concordant positive serum allergen-specific IgE test and
IgE skin prick test results were observed in 928 (99.6%)
of the 932 children in the mITT population.
Primary efficacy analysis
Fexofenadine was significantly superior to placebo in
the PM-reflective TSS (P ≤ .0001; Fig 1). The mean
change from baseline was 1.94 for the fexofenadine-
treated group and 1.21 for the placebo group.
Secondary efficacy analysis
Fexofenadine HCl 30 mg bid significantly improved
the average AM-reflective TSS compared with placebo (P
≤ .0001). The change from baseline was –1.67 for the
fexofenadine-treated group and –0.93 for the placebo
group. The mean changes from baseline and treatment
difference were consistent with those seen in the PM-
reflective TSS assessment. In the fexofenadine HCl 30
mg bid group, all PM-reflective individual symptom
scores, including nasal congestion, were significantly
reduced compared with placebo (sneezing, P ≤ .0001;
rhinorrhea, P = .0005; itchy nose, palate, throat, and/or
ears, P ≤ .0001; itchy, watery, red eyes, P ≤ .0001; nasal
congestion P = .0079; Fig 2). The AM-reflective assess-
ment individual symptom scores were significantly
reduced compared with placebo and were comparable to
those observed when measured for the PM-reflective
assessments (sneezing, P ≤ .0001; rhinorrhea, P = .0006;
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FIG 1. Mean (± SE) change in PM-reflective total symptom score (TSS) with modified intention-to-treat
(mITT) population. ***P ≤ .0001 versus placebo. 
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itchy nose, palate, throat, and/or ears, P ≤ .0001; itchy,
watery, red eyes, P ≤ .0001). Nasal congestion showed a
trend toward improvement in the AM-reflective assess-
ment compared with placebo (P = .0952).
Assessment of the daily PM-reflective TSS showed
that the improvement in TSS with fexofenadine HCl 30
mg bid was statistically superior to placebo for each day
of the 14-day double-blind treatment period. A signifi-
cant improvement compared with placebo was observed
from the first day on treatment (P ≤ .0001) and was
maintained throughout the entire treatment period (P <
.0007, day 14; Fig 3). 
For all efficacy variables, comparable results were
obtained when the PP population was used for analysis.
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FIG 2. Twelve-hour PM-reflective individual symptom scores with modified intention-to-treat (mITT) popula-
tion. All P values are for the treatment group versus placebo. *P < .01. **P < .001. ***P ≤ .0001.
TABLE I. Demographic and baseline characteristics for modified intention-to-treat population
Characteristic Placebo Fexofenadine HCl
Total treated (%) 469 (100.0) 463 (100.0)
Age (y)
Mean ± SD 8.8 ± 1.6 8.8 ± 1.6
Median (range) 9 (5-12) 9 (6-12)
Race
White N (%) 373 (79.5) 377 (81.4)
Black N (%) 33 (7.0) 34 (7.3)
Asian/Oriental N (%) 7 (1.5) 6 (1.3)
Multiracial N (%) 56 (11.9) 46 (9.9)
Randomization baseline PM
TSS (mean ± SD) 7.07 ± 0.103 6.80 ± 0.097
Sneezing (mean ± SD) 1.75 ± 0.035 1.69 ± 0.035
Rhinorrhea (mean ± SD) 1.94 ± 0.034 1.89 ± 0.034
Itchy nose, mouth, throat and/or ears (mean ± SD) 1.76 ± 0.036 1.68 ± 0.037
Itchy, watery, red eyes (mean ± SD) 1.62 ± 0.041 1.53 ± 0.040
Nasal congestion (mean ± SD) 1.79 ± 0.039 1.78 ± 0.038
Male Female Male Female
Sex: N (%) 312 (66.5) 157 (33.5) 278 (60.0) 185 (40.0)
Weight (kg)
N 311 156 278 185
Mean ± SD 34.6 ± 11.3 33.1 ± 10.6 33.9 ± 9.6 33.8 ± 11.7
Median (range) 33.0 (15.5-83.9) 30.8 (16.0-68.9) 32.0 (17.5-60.3) 32.0 (19.0-114.8)
Height (cm)
N 312 157 276 185
Mean ± SD 136.7 ± 12.1 135.5 ± 12.3 136.5 ± 10.7 135.2 ± 11.5
Median (range) 137.0 (102.0-172.7) 134.6 (107.0-164.0) 136.0 (111.0-164.0) 135.0 (110.0-162.0)
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Safety analysis
In all, 935 children received at least 1 dose of the dou-
ble-blind treatment and were therefore included in the
safety analysis. The frequency of TEAEs was similar
between the fexofenadine (85 of 464, 18.3%) and place-
bo (88 of 471, 18.7%) groups. The number of TEAEs
possibly related to treatment was also comparable. A
total of 2.7% (25) of the 935 children (fexofenadine, n =
14; placebo, n = 11) reported at least 1 TEAE possibly
related to treatment. None of the possibly related TEAEs
occurred in >1% of children (Table II).
Three children in the fexofenadine-treated group expe-
rienced TEAEs that led to withdrawal from the study, but
these were not considered to be related to treatment
(asthma, n = 1; upper respiratory infection, n = 1; vomit-
ing, n = 1). One child experienced a serious adverse
event, neutropenia, in the fexofenadine-treated group on
routine evaluation that was thought to be related to treat-
ment. Laboratory tests of the aforementioned child
revealed decreased neutrophil levels on day 15 after 14
days of double-blind treatment: 0.4 × 109/L compared
with 2.3 × 109/L at screening. This serious adverse event
was reported as mild in intensity, and the child was
asymptomatic and recovered without sequelae. Total
leukocyte counts for this child remained stable during the
follow-up but below the normal range of screening.
Because serologic work was consistent with recent sero-
conversions for Mycoplasma pneumoniae and Varicella
IgG, subclinical infections might offer an alternative
explanation for the event. 
There were no significant differences in changes in
clinical laboratory and vital signs results between the
fexofenadine- and placebo-treated groups. 
DISCUSSION
Allergic rhinitis might exacerbate and contribute to the
symptoms of several comorbid conditions. The high
prevalence of concomitant rhinitis and asthma is reported
in the ARIA guidelines,26 which propose the concept that
these might be local manifestations of “one-airway, one
disease.” Indeed, in patients with concomitant rhinitis and
asthma, antihistamine treatment has shown significant
improvement in both disorders.27,28 Furthermore, previ-
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FIG 3. Daily PM-reflective total symptom score (TSS) during double-blind treatment period—modified inten-
tion-to-treat (mITT) population. The arrow above the graph indicates the first point at which the effects of treat-
ment would be observed (Day 2); Day 1 corresponds to the baseline (B). *P < .01. **P < .001. ***P ≤ .0001.
TABLE II. Treatment emergent adverse events (>1%)—
safety double-blind population
No. of children (%)
Placebo Fexofenadine HCl
Total in safety double-blind 471 (100.0) 464 (100.0)
population
Total with TEAEs* 88 (18.7) 85 (18.3)
Headache 13 (2.8) 23 (5.0)
Epistaxis 5 (1.1) 7 (1.5)
Upper respiratory infection 5 (1.1) 7 (1.5)
Pharyngitis 1 (0.2) 6 (1.3)
Sinusitis 0 (0.0) 6 (1.3)
Nausea 1 (0.2) 5 (1.1)
Rash 3 (0.6) 5 (1.1)
Accidental injury 6 (1.3) 4 (0.9)
Asthma 9 (1.9) 3 (0.6)
Infection 5 (1.1) 1 (0.2)
Gastrointestinal pain 5 (1.1) 1 (0.2)
Treatment-emergent adverse events (TEAEs) were classified according to
the HART coding system.
*P = 1.00 incidence of all TEAEs between fexofenadine and placebo by
Fisher exact test.
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ous studies have indicated that early intervention in the
treatment of allergies could help prevent progression to
other allergic disorders, such as asthma.29,30
Few studies in children with allergic rhinitis have
involved objective efficacy end points.31,32 No objective
end points are currently required by the regulatory agen-
cies for the assessment of drug efficacy for SAR treat-
ment, and the efficacy of antihistamines in adults has
been established with the standard and accepted TSS
assessment. The measures of effectiveness in allergic
rhinitis trials preferred by regulatory agencies are
patients’ self-related composite symptom scores and the
resulting TSSs. The results of this study demonstrate that
fexofenadine HCl (30 mg bid) is effective in reducing
both the TSS and individual symptom scores of SAR
compared with placebo. These effects were maintained
throughout the entire 2-week, double-blind treatment
period. The results of this study support previous data in
which 30 or 60 mg fexofenadine HCl has been shown to
suppress histamine-induced wheal and flare within 1 to 2
hours in children.24
A number of other studies have examined the effects
of antihistamines in children with SAR.13-19 However,
only one of these studies, which investigated the effects
of cetirizine (5 and 10 mg 4 times per day [qid]) in a ran-
domized, double-blind, placebo-controlled trial of chil-
dren with SAR aged 6 to 11 years, used symptom scor-
ing similar to that used in adult studies.13 This study
showed that cetirizine (10 mg qid) is effective in the
treatment of SAR (n = 209), as assessed by measurement
of the TSS, in 2 of 4 weeks; the first week of treatment
did not reach statistical significance. In this study the
TSS corresponded to the sum of the individual symptoms
of sneezing, nasal discharge, itchy eyes, itchy nose or
mouth, and conjunctivitis but excluded nasal congestion.
Assessment of individual symptoms showed that ceti-
rizine (10 mg qid) demonstrated a significant decrease in
the symptoms of itchy eye and itchy nose or mouth.
There were no statistically significant differences from
placebo for nasal discharge, conjunctivitis, sneezing, or
nasal congestion with cetirizine (10 mg). 
Traditionally, antihistamines have not been considered
effective in relieving nasal congestion; accordingly, sec-
ond-generation antihistamines are not indicated for the
relief of nasal congestion. Nasal congestion is considered
a vascular response involving a wide range of mediators,
such as kinins, prostaglandin D2, and leukotrienes. In the
current study, fexofenadine HCl 30 mg bid showed sta-
tistically significant efficacy in relieving all symptoms of
SAR, including ocular symptoms and nasal congestion.
In the AM-reflective assessment, nasal congestion showed
a trend toward improvement (P = .0952). Similarly, other
studies in adults with SAR have shown significant effica-
cy with fexofenadine in relieving all symptoms of
SAR.20,22,33 The effect of fexofenadine on nasal conges-
tion might reflect an activity that is broader than its
antagonism at the H1-receptor. Numerous in vitro studies
with fexofenadine have highlighted the potential of this
agent to produce significant anti-inflammatory effects at
clinically relevant concentrations,34-38 and it is hypothe-
sized that these effects might contribute to inhibition of
the late-phase response.37
In this large pediatric population, the incidence and
severity of reported adverse events with fexofenadine
were similar to those for placebo. The results of this
trial confirm previous findings in which fexofenadine
HCl at doses of up to 60 mg bid are safe and nonsedat-
ing in children aged 6 to 11 years.25 This finding is fur-
ther supported by the results of dose-response trials in
healthy individuals, in which doses of up to 690 mg bid
for 1 month were found to be safe and well-tolerat-
ed.39,40 Extensive studies in children and adults have
also shown no effect of fexofenadine on QTc compared
with placebo.24,25,41 The proven efficacy of fexofena-
dine, in combination with its nonsedating and nonim-
pairing profile, evident even at doses in excess of those
recommended by the manufacturer, offers validation for
its use in the treatment of all symptoms of allergic rhini-
tis in children and adults.
In conclusion, previous studies have demonstrated
that the pharmacokinetics and pharmacologic effects of
fexofenadine in children are similar to those in adults
and that fexofenadine is safe and well-tolerated in chil-
dren aged 6 to 11 years. The results of this study clear-
ly demonstrate that fexofenadine HCl 30 mg bid tablets
are effective at reducing the symptoms of SAR, includ-
ing nasal congestion, in children aged 6 to 11 years; this
effect was maintained throughout the entire 2-week
study period.
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